The effects of acutely administered 3, 4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity
This double-blind, placebo-controlled, balanced-order, within-subjects study (n=25) investigated how the subjective effects of MDMA are related to its neural effects .fMRI scans during MDMA use showed changes in cerebral blood flow in the right medial temporal lobe, thalamus, inferior visual cortex, somatosensory cortex, right amygdala and hippocampus, as well as decreased resting-state functional connectivity (RSFC) between midline cortical regions, the medial prefrontal cortex, and the medial temporal lobe, and increased RSFC between the amygdala and hippocampus.
Authors
- Bloomfield, M.
- Bolstridge, M.
- Brugger, S.
Published
Abstract
Background: The compound 3,4-methylenedioxymethamphetamine (MDMA) is a potent monoamine releaser that produces an acute euphoria in most individuals.Methods: In a double-blind, placebo-controlled, balanced-order study, MDMA was orally administered to 25 physically and mentally healthy individuals. Arterial spin labeling and seed-based resting state functional connectivity (RSFC) were used to produce spatial maps displaying changes in cerebral blood flow (CBF) and RSFC after MDMA administration. Participants underwent two arterial spin labeling and two blood oxygen level-dependent scans in a 90-minute scan session; MDMA and placebo study days were separated by 1 week.Results: Marked increases in positive mood were produced by MDMA. Decreased CBF only was observed after MDMA, and this was localized to the right medial temporal lobe (MTL), thalamus, inferior visual cortex, and the somatosensory cortex. Decreased CBF in the right amygdala and hippocampus correlated with ratings of the intensity of global subjective effects of MDMA. The RSFC results complemented the CBF results, with decreases in RSFC between midline cortical regions, the medial prefrontal cortex, and MTL regions, and increases between the amygdala and hippocampus. There were trend-level correlations between these effects and ratings of intense and positive subjective effects.Conclusions: The MTLs appear to be specifically implicated in the mechanism of action of MDMA, but further work is required to elucidate how the drug’s characteristic subjective effects arise from its modulation of spontaneous brain activity.
Research Summary of 'The effects of acutely administered 3, 4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity'
Study Details
- Study Typeindividual
- Populationhumans
- Characteristicsdouble blindplacebo controlledcrossoverbrain measures
- Journal
- Compounds
- Topics
Cited By (34)
Papers in Blossom that reference this study
Agin-Liebes, G. I., Mitchell, J., Zeifman, R. J. · European Journal of Psychotraumatology (2025)
Ashraf, I., Azizi, L., Carhart-Harris, R. L. et al. · Biorxiv (2025)
Agnorelli, C., Bohl, B., Carhart-Harris, R. L. et al. · Preprints (2024)
Alpert, M., Mithoefer, A. T., Mithoefer, M. C. et al. · Frontiers in Psychology (2024)
Argento, E., Brendle, M., Girn, M. et al. · Journal of Psychopharmacology (2024)
Godes, M., Lucas, J., Vermetten, E. · Frontiers in Psychiatry (2023)
Anand, A., Carhart-Harris, R. L., Ertl, N. et al. · Journal of Affective Disorders (2023)
Duthaler, U., Eckert, A., Liechti, M. E. et al. · Frontiers in Pharmacology (2022)
Coker, A., Doblin, R., Emerson, A. et al. · Frontiers in Psychiatry (2022)
Burton, M., Coghlan, C., Dunlop, B. W. et al. · Journal of Psychopharmacology (2022)
Show all 34 papersShow fewer
Aday, J. S., Curran, H. V., Higbed, L. et al. · Journal of Psychopharmacology (2021)
Albrecht, M., Chaliha, D., Lam, V. et al. · Current Neuropharmacology (2021)
Bird, C. I. V., Modlin, N. L., Rucker, J. · International Review of Psychiatry (2021)
Andries, J., Carlin, S. C., Doblin, R. et al. · Scientific Reports (2020)
Forbes, D., Gibson, K., Varker, T. et al. · Journal of Psychoactive Drugs (2020)
Breeksema, J. J., Krediet, E., Niemeijer, A. R. et al. · CNS Drugs (2020)
Bostoen, T., Breeksema, J. J., Krediet, E. et al. · International Journal of Neuropsychopharmacology (2020)
Carhart-Harris, R. L., Demetriou, L., Mertens, L. J. et al. · Journal of Psychopharmacology (2020)
Durai, M., Kennedy, M. A., Maggo, S. et al. · International Journal of Neuroscience (2020)
Doblin, R., Emerson, A., Feduccia, A. A. et al. · Frontiers in Psychiatry (2019)
Dipasquale, O., Gabay, A. S., Mehta, M. A. et al. · NeuroImage (2019)
Nutt, D. J. · Dialogues in Clinical Neuroscience (2019)
Mithoefer, A. T., Mithoefer, M. C., Monson, C. M. et al. · Journal of Psychoactive Drugs (2019)
Doblin, R., Emerson, A., Feduccia, A. A. et al. · Journal of Psychopharmacology (2018)
Danforth, A. L., Emerson, A., Feduccia, A. A. et al. · Psychopharmacology (2018)
Feduccia, A. A., Mithoefer, M. C. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)
Carhart-Harris, R. L., Gabay, A. S., Kempton, M. J. et al. · Scientific Reports (2018)
Bolstridge, M., Carhart-Harris, R. L., Curran, H. V. et al. · Scientific Reports (2017)
Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)
Carhart-Harris, R. L., Evans, J., Nour, M. R. et al. · Frontiers in Human Neuroscience (2016)
Bolstridge, M., Carhart-Harris, R. L., Curran, H. V. et al. · PNAS (2016)
Andero, R., Howell, L. L., Ressler, K. J. et al. · Translational Psychiatry (2015)
Nutt, D. J., Sessa, B. · British Journal of Psychiatry (2015)
Carhart-Harris, R. L., Feilding, A., Leech, R. et al. · Frontiers in Human Neuroscience (2014)